Acadia Pharmaceuticals Secures Exclusive Licensing Deal for Saniona’s Tremor Treatment Asset Worth Up to $582 Million

Deal Value:
Acadia Pharmaceuticals has entered into an exclusive licensing deal worth up to $582 million biobucks for Saniona's neurological disorder asset focused on tremor treatment12.

Partnership:
The deal signifies a strategic partnership between Acadia Pharmaceuticals and Saniona, aimed at advancing the development of the tremor treatment asset.

Asset Focus:
The licensed asset is specifically designed to address neurological disorders, particularly those involving tremors.

Financial Terms:
The deal includes potential payments totaling up to $582 million, contingent on certain milestones and performance criteria.

Date of Agreement:
The agreement was announced on November 26, 202412.

Sources:

1. https://www.fiercebiotech.com/biotech/acadia-nabs-rights-sanionas-tremor-asset-582m-biobucks-deal

2. https://sdbn.org/san-diego-biotech-news/2024/11/26/acadia-nabs-rights-to-sanionas-tremor-asset-in-582m-biobucks-deal/